Nisa Investment Advisors LLC Purchases 8,294 Shares of Amgen Inc. $AMGN

Key Points

• Nisa Investment Advisors increased its Amgen position by 5.2%, buying 8,294 shares to own 167,256 shares valued at approximately $70.5 million. Institutional investors collectively hold 76.5% of AMGN.
• Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $387.93, despite targets ranging as high as $500.
• Amgen reported quarterly results above expectations, including $6.29 EPS and $10.05 billion in revenue, up 9.5% year over year. The company also pays a quarterly dividend of $2.52 per share, representing a 2.3% annualized yield.

Nisa Investment Advisors LLC grew its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 167,256 shares of the medical research company's stock after buying an additional 8,294 shares during the period. Nisa Investment Advisors LLC's holdings in Amgen were worth $70,500,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of AMGN. Rational Advisors Inc. grew its holdings in shares of Amgen by 13.7% during the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company's stock valued at $72,000 after buying an additional 24 shares during the last quarter. Beacon Financial Advisory LLC increased its position in shares of Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company's stock valued at $461,000 after acquiring an additional 25 shares in the last quarter. James T. Borello RIA raised its holdings in Amgen by 13.6% in the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company's stock worth $88,000 after acquiring an additional 25 shares during the last quarter. Sweeney & Michel LLC raised its holdings in Amgen by 0.5% in the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company's stock worth $2,162,000 after acquiring an additional 25 shares during the last quarter. Finally, Legacy Financial Advisors Inc. raised its holdings in Amgen by 0.8% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company's stock worth $1,234,000 after acquiring an additional 26 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMGN shares. BMO Capital Markets lowered their price objective on Amgen from $450.00 to $415.00 and set a "market perform" rating on the stock in a research report on Monday, October 12th. UBS Group lifted their target price on Amgen from $430.00 to $470.00 and gave the stock a "buy" rating in a report on Friday, October 9th. Wells Fargo & Company reduced their target price on Amgen from $435.00 to $430.00 and set an "equal weight" rating for the company in a report on Monday, October 12th. Morgan Stanley decreased their price target on Amgen from $362.00 to $359.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 7th. Finally, Scotiabank upped their price target on Amgen from $450.00 to $500.00 and gave the company an "outperform" rating in a report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $387.93.

Amgen Stock Up 3.3%

AMGN opened at $438.94 on Wednesday. The stock has a market capitalization of $237.30 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 3.11 and a beta of 0.41. The firm has a 50 day moving average price of $416.19 and a 200-day moving average price of $376.06. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. During the same quarter last year, the company posted $6.02 earnings per share. The firm's quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's dividend payout ratio is presently 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Tezspire Phase 3 results: Amgen and AstraZeneca reported that Tezspire produced statistically significant and clinically meaningful improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. The data could expand Tezspire’s commercial opportunity beyond severe asthma. Tezspire Phase 3 results
• Positive Sentiment: Upcoming oncology presentation: Amgen will host an investor webcast during the European Society for Medical Oncology Congress on October 24. New cancer-drug data could provide additional visibility into the company’s pipeline and growth prospects. Amgen ESMO 2026 presentation
• Positive Sentiment: Higher analyst valuation: Goldman Sachs raised its price target for AMGN to $481, signaling potential upside from recent trading levels and reinforcing improving sentiment toward the company. Goldman Sachs raises Amgen price target
• Positive Sentiment: Strong financial performance: Amgen recently exceeded consensus estimates for quarterly revenue and earnings per share, with revenue up 9.5% year over year. Investors are increasingly viewing the company’s diversified portfolio as capable of delivering renewed growth.
• Neutral Sentiment: Compared with Bristol Myers Squibb, Amgen offers stronger recent top-line growth, while Bristol Myers has a lower valuation and substantial free cash flow. The comparison highlights AMGN’s growth appeal but also its relatively fuller valuation. Amgen versus Bristol Myers Squibb
• Negative Sentiment: At roughly 27 times earnings, AMGN is not a deep-value healthcare stock, and its high debt-to-equity ratio increases sensitivity to execution and pipeline setbacks. Investors still need evidence that newer products can sustain growth as mature medicines face competition.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 over the last three months. Insiders own 0.85% of the company's stock.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.